361 Capital’s Editas Medicine EDIT Stock Holding History

361 Capital’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-94,986	Closed	-$2.35M	–	329
2019 Q2	$2.35M	Sell	94,986 -6,752	-7%	-$161K	0.42%	130
2019 Q1	$2.49M	Buy	101,738 +9,564	+10%	+$216K	0.43%	127
2018 Q4	$2.1M	Buy	+92,174	New	+$2.51M	0.43%	121
2018 Q3	–	Sell	-45,215	Closed	-$1.62M	–	354
2018 Q2	$1.62M	Buy	+45,215	New	+$1.6M	0.37%	138

Other funds holding EDIT

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

361 Capital's EDIT Position: Q3 2019 in Review

361 Capital sold out of Editas Medicine (EDIT) in Q3 2019, closing a stake of 94,986 shares — an estimated $2.35M sold.

361 Capital first reported a position in EDIT in Q2 2018 and held it in 4 quarters. The position peaked at $2.49M in Q1 2019. 187 funds tracked by Wall St. Rank hold EDIT as of Q3 2019.

361 Capital reported no remaining Editas Medicine position as of Q3 2019 after selling out during the quarter.
361 Capital sold 94,986 Editas Medicine shares in Q3 2019, an estimated $2.35M.
361 Capital first reported a position in Editas Medicine in Q2 2018 and held it in 4 quarters.
361 Capital's Editas Medicine position peaked at $2.49M in Q1 2019.
187 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2019.

Based on 361 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.